Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
Gizem Kaykı-Mutlu, Martin C. Michel
Naunyn-Schmiedeberg s Archives of Pharmacology (2021) Vol. 394, Iss. 5, pp. 839-852
Open Access | Times Cited: 11

Showing 11 citing articles:

The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine
Qian Wang, Jianlin Han, Alexander E. Sorochinsky, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 8, pp. 999-999
Open Access | Times Cited: 42
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2024
Zinnet Şevval Aksoyalp, Gizem Kaykı-Mutlu, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2021
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2022) Vol. 395, Iss. 8, pp. 867-885
Open Access | Times Cited: 17
Pharmacological profile of novel anti-cancer drugs approved by USFDA in 2022: A Review
Kavita Sangwan, Vipasha Sharma, Parveen Kumar Goyal
Current Molecular Medicine (2023) Vol. 24, Iss. 6, pp. 734-750
Closed Access | Times Cited: 7
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2023
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 5, pp. 2949-2970
Open Access | Times Cited: 2
A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2022
Gizem Kaykı-Mutlu, Zinnet Şevval Aksoyalp, Leszek Wojnowski, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 396, Iss. 8, pp. 1619-1632
Open Access | Times Cited: 5
Relugolix in the management of prostate cancer
Kamal Kant Sahu, Nishita Tripathi, Neeraj Agarwal, et al.
Expert Review of Anticancer Therapy (2022) Vol. 22, Iss. 9, pp. 891-902
Closed Access | Times Cited: 6
Serial triphenylpropionic acid and N,N'-chelator mixed ligands Cu(II) complexes: structure and biological properties
Jing Feng, Jing Liu, Yizhu Lei, et al.
Journal of Molecular Structure (2024) Vol. 1321, pp. 139773-139773
Closed Access
In vitro and in vivo antiplasmodial activity of a synthetic dihydroartemisinin–eosin B hybrid
Hajar Karimi Askarani, Azar Tahghighi, M Erfanian Ahmadpoor, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2023) Vol. 397, Iss. 6, pp. 4013-4024
Closed Access
Fresh Baked: An Overview of Newly FDA-Approved Drugs for Dermatological Usage
Bartika Sikder, Abheek Sil
Indian Journal of Dermatology (2023) Vol. 68, Iss. 6, pp. 707-720
Open Access
Neue Arzneimittel 2020
Lutz Hein, Roland Seifert
Springer eBooks (2021), pp. 37-55
Closed Access
Page 1

Scroll to top